Drug Type TCR-T Cell therapy |
Synonyms |
Target |
Action antagonists |
Mechanism MAGEC2 antagonists(MAGE family member C2 antagonists), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anus Neoplasms | Preclinical | United States | 01 Dec 2024 | |
Head and Neck Neoplasms | Preclinical | United States | 01 Dec 2024 | |
Non-Small Cell Lung Cancer | Preclinical | United States | 01 Dec 2024 | |
Sarcoma | Preclinical | United States | 01 Dec 2024 | |
Uterine Cervical Cancer | Preclinical | United States | 01 Dec 2024 |